POTASSIUM PHOSPHATE, DIBASIC, TRIHYDRATE

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	2K.HO4P.3H2O
Molecular Weight	228.2217
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of POTASSIUM PHOSPHATE, DIBASIC, TRIHYDRATE

Structure Search

SMILES

O.O.O.[K+].[K+].OP([O-])([O-])=O

InChI

InChIKey=XQGPKZUNMMFTAL-UHFFFAOYSA-L

InChI=1S/2K.H3O4P.3H2O/c;;1-5(2,3)4;;;/h;;(H3,1,2,3,4);3*1H2/q2*+1;;;;/p-2

HIDE SMILES / InChI

Molecular Formula	H3O4P
Molecular Weight	97.9952
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	K
Molecular Weight	39.0983
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21250045https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/18582scs031_procalAmine_lbl.pdf | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58f0330d-0c16-4505-913d-26cccf42ae99

Phosphoric acid, also known as orthophosphoric acid, is used in dentistry and orthodontics to clean and roughen the surfaces of teeth where dental appliances or fillings will be placed. In addition, this acid is a part of product ProcalAmine, which is indicated for peripheral administration in adults to preserve body protein and improve nitrogen balance in well-nourished, mildly catabolic patients who require short-term parenteral nutrition. In combination with dextrose (glucose) and levulose (fructose), phosphoric acid relieves nausea due to upset stomach from intestinal flu, stomach flu, and food or drink indiscretions. In addition, homeopathic product, Brain power contains also phosphoric acid and this product is used to temporarily relieve symptoms of general physical weakness and listlessness, including: fatigue; sore muscles & joints; dry skin; absence of sexual desire; occasional sleeplessness.

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Lose body protein 27 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/18582scs031_procalAmine_lbl.pdf	Palliative	Approved 8429	PROCALAMINE Approved Use ProcalAmine is indicated for peripheral administration in adults to preserve body protein and improve nitrogen balance in well-nourished, mildly catabolic patients who require short-term parenteral nutrition. Launch Date 3.89664014E11
Nausea 63 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8dc39e1-e03e-4db8-a76d-dba72aad9a49	Palliative	Not Provided 504	Unknown Approved Use Unknown
Fatigue 46 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58f0330d-0c16-4505-913d-26cccf42ae99	Palliative	Not Provided 504	Unknown Approved Use Unknown
Occasional sleeplessness 37 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58f0330d-0c16-4505-913d-26cccf42ae99	Palliative	Not Provided 504	Unknown Approved Use Unknown
Sore muscles & joints 27 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58f0330d-0c16-4505-913d-26cccf42ae99	Palliative	Not Provided 504	Unknown Approved Use Unknown
Hypophosphatemia 30 Sources: http://www.iasj.net/iasj?func=fulltext&aId=44752	Diagnostic	Natural Metabolite	Unknown Approved Use Unknown
Hyperphosphatemia 30 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21250045	Diagnostic	Natural Metabolite	Unknown Approved Use Unknown
Hypophosphatemia 30 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3d066575-f361-4fcc-b1f3-3ae2be447719&type=display	Primary	Approved 8429	SODIUM PHOSPHATES INJECTION Approved Use Sodium Phosphates Injection, USP, 3mM P/mL, is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of sodium (4 mEq/mL) must be calculated into total electrolyte content of such prepared solutions.

PubMed

Title	Date	PubMed
Diurnal variation in the levels of glucose and related substances in healthy and diabetic subjects during starvation.	1967 Feb	5336272
Determination of inorganic phosphate in serum and saliva using a synthetic receptor.	2003 Jun 12	12790520
Amperometric biosensor for determining human salivary phosphate.	2005 Aug 15	15993373
Phosphorus amendment reduces hepatic and renal oxidative stress in mallards ingesting lead-contaminated sediments.	2006 Jun	16840252

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:03:33 UTC 2023` Edited by `admin` on `Fri Dec 15 16:03:33 UTC 2023`
Record UNII	RJK174X3TZ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

POTASSIUM PHOSPHATE, DIBASIC, TRIHYDRATE

Common Name

English

POTASSIUM PHOSPHATE DIBASIC TRIHYDRATE

Common Name

English

DIPOTASSIUM HYDROGEN PHOSPHATE TRIHYDRATE

Systematic Name

English

DIPOTASSIUM PHOSPHATE TRIHYDRATE

Systematic Name

English

PHOSPHORIC ACID, DIPOTASSIUM SALT, TRIHYDRATE

Common Name

English

DIPOTASSIUM MONOPHOSPHATE TRIHYDRATE

Systematic Name

English

DIPOTASSIUM HYDROGEN PHOSPHATE, TRIHYDRATE

Systematic Name

English

DIPOTASSIUM ORTHOPHOSPHATE, TRIHYDRATE

Systematic Name

English

DIPOTASSIUM HYDROGEN PHOSPHATE (K2HPO4) TRIHYDRATE

Common Name

English

Code System Code Type Description

EPA CompTox

DTXSID60168418